[Br:1][C:2]1[CH:7]=[CH:6][C:5]([NH:8][C:9]2[C:17]([C:18]([OH:20])=O)=[CH:16][CH:15]=[C:14]3[C:10]=2[CH:11]=[N:12][NH:13]3)=[C:4]([F:21])[CH:3]=1.Cl.[NH2:23][O:24][CH2:25][C@@H:26]([OH:28])[CH3:27].CCN=C=NCCCN(C)C.C1C=CC2N(O)N=NC=2C=1.CCN(C(C)C)C(C)C>CN(C=O)C>[OH:28][C@@H:26]([CH3:27])[CH2:25][O:24][NH:23][C:18]([C:17]1[C:9]([NH:8][C:5]2[CH:6]=[CH:7][C:2]([Br:1])=[CH:3][C:4]=2[F:21])=[C:10]2[C:14](=[CH:15][CH:16]=1)[NH:13][N:12]=[CH:11]2)=[O:20]To a solution of 4-(4-bromo-2-fluorophenylamino)-1H-indazole-5-carboxylic acid (115 mg, 0.33 mmol) and (S)-1-aminooxy-propan-2-ol hydrochloride (63 mg, 0.49 mmol) in DMF (3 mL) was added EDCI (69 mg, 0.36 mmol), HOBt (49 mg, 0.36 mmol) and DIPEA (150 μL, 0.85 mmol). The reaction mixture was stirred at room temperature for 16 hours before being concentrated in vacuo. The resultant residue was dissolved in ethyl acetate (10 mL), washed with aqueous saturated sodium bicarbonate solution (10 mL) and the aqueous fraction extracted twice with ethyl acetate (2×10 mL). The combined organic fractions were washed with brine (20 mL), dried (MgSO4) and concentrated in vacuo. The resultant residue was subjected to reverse phase preparative HPLC (10-90% acetonitrile/water 0.1% formic acid, Phenominex gemini PhC6, 5 micron, 250×20 mm). The resultant product was dissolved in ethyl acetate (5 mL) and washed with aqueous saturated sodium bicarbonate solution (10 mL). The aqueous fraction was extracted twice with ethyl acetate (2×10 mL) and the combined organic layers washed with brine (20 mL), dried (MgSO4) and concentrated in vacuo to yield the title compound as a white solid (61 mg, 44%). LCMS (Method A): RT=8.45 min, [M+H]+=423/425. 1H NMR (DMSO-d6, 400 MHz) 13.21 (1H, s), 11.63 (1H, s), 9.90 (1H, s), 7.58 (1H, dd, J=10.47, 2.24 Hz), 7.46 (1H, d, J=8.75 Hz), 7.29 (1H, ddd, J=8.59, 2.19, 1.06 Hz), 7.23 (1H, s), 7.08 (1H, t, J=8.80 Hz), 7.02 (1H, d, J=8.78 Hz), 4.77 (1H, d, J=4.15 Hz), 3.84-3.78 (1H, m), 3.70-3.61 (2H, m), 1.03 (3H, d, J=6.33 Hz).
読み込み中…